Marina N Magrey1,2, Muhammad A Khan3. 1. Case Western Reserve University School of Medicine, Cleveland, OH, 44109, USA. mmagrey@metrohealth.org. 2. MetroHealth Medical Center, Cleveland, OH, 44109, USA. mmagrey@metrohealth.org. 3. Division of Rheumatology, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Abstract
PURPOSE OF REVIEW: The purpose of the study is to briefly review the molecular mechanisms that leads to structural damage in ankylosing spondylitis (AS), defined as new bone formation resulting in complete or incomplete ankylosis of the spine, and the impact of treatment with biologics to retard this process. RECENT FINDINGS: The understanding of molecular mechanisms leading to new bone formation in AS has significantly improved but is still incomplete. Availability of biologics has greatly enhanced the treatment of patients with AS, but its impact on slowing the structural damage is still a matter of debate, although a few observational studies have shown that long term use of TNF-α blockers may slow radiographic progression. The availability of newer biologics targeting IL-17/1L23 has shown some promising results in slowing radiographic progression in AS. Although the availability of TNF-inhibitors has greatly enhanced the treatment options for patients with AS, their impact on slowing the structural damage is still not clearly established. However, preliminary results using newer biologics targeting IL-17/1L23 axis are more encouraging but longer follow-up is needed.
PURPOSE OF REVIEW: The purpose of the study is to briefly review the molecular mechanisms that leads to structural damage in ankylosing spondylitis (AS), defined as new bone formation resulting in complete or incomplete ankylosis of the spine, and the impact of treatment with biologics to retard this process. RECENT FINDINGS: The understanding of molecular mechanisms leading to new bone formation in AS has significantly improved but is still incomplete. Availability of biologics has greatly enhanced the treatment of patients with AS, but its impact on slowing the structural damage is still a matter of debate, although a few observational studies have shown that long term use of TNF-α blockers may slow radiographic progression. The availability of newer biologics targeting IL-17/1L23 has shown some promising results in slowing radiographic progression in AS. Although the availability of TNF-inhibitors has greatly enhanced the treatment options for patients with AS, their impact on slowing the structural damage is still not clearly established. However, preliminary results using newer biologics targeting IL-17/1L23 axis are more encouraging but longer follow-up is needed.
Entities:
Keywords:
Ankylosing spondylitis; Axial spondyloarthritis; Bone morphogenetic proteins; Il-17 inhibitors; MicroRNAs; New bone formation; Osteoporosis; Osteoproliferation; Syndesmophytes; TNF-α inhibitors; Wnt signaling pathways
Authors: C H Im; E H Kang; J Y Ki; D W Shin; H J Choi; E J Chang; E Y Lee; Y J Lee; E B Lee; H H Kim; Y W Song Journal: Clin Exp Rheumatol Date: 2009 Jul-Aug Impact factor: 4.473
Authors: Nigil Haroon; Robert D Inman; Thomas J Learch; Michael H Weisman; MinJae Lee; Mohammad H Rahbar; Michael M Ward; John D Reveille; Lianne S Gensler Journal: Arthritis Rheum Date: 2013-10
Authors: Nicole C Walsh; Susan Reinwald; Catherine A Manning; Keith W Condon; Ken Iwata; David B Burr; Ellen M Gravallese Journal: J Bone Miner Res Date: 2009-09 Impact factor: 6.741
Authors: Dimitrios Daoussis; Stamatis-Nick C Liossis; Elena E Solomou; Anastasia Tsanaktsi; Konstadina Bounia; Maria Karampetsou; Georgios Yiannopoulos; Andrew P Andonopoulos Journal: Arthritis Rheum Date: 2010-01
Authors: Tae-Han Lee; Bon San Koo; Bora Nam; Ji Seon Oh; Seo Young Park; Seunghun Lee; Kyung Bin Joo; Tae-Hwan Kim Journal: Ther Adv Musculoskelet Dis Date: 2020-11-28 Impact factor: 5.346